Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature reviewS Hager, C J Ackermann, M Joerger, et al.
Lung Cancer (Amsterdam, Netherlands)|December 4, 2014
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinomaS Schmid, M Siano, M Joerger, et al.
Leukemia & Lymphoma|April 26, 2012
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphomaM Joerger, A D R Huitema, G Illerhaus, et al.
Cancer Chemotherapy and Pharmacology|August 5, 2010
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonatesM Joerger, A Templeton, D Köberle, et al.
Investigational New Drugs|February 20, 2015
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumorsM Joerger, D Hess, A Delmonte, et al.
Urology|April 10, 2004
Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancerM Joerger, T Warzinek, B Klaeser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2010
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysisM Joerger, K Matter-Walstra, M Früh, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2005
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcomaM Joerger, A D R Huitema, P L Meenhorst, et al.
Chemotherapy|July 11, 2013
Management of elderly patients with advanced non-small cell lung cancer: a single-center experienceM Früh, H Besrour, S Gillessen, et al.
The Pharmacogenomics Journal|March 23, 2016
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicityS Hamzic, N Wenger, T K Froehlich, et al.
Pageof 5